Table 3. Multivariate logistic regression analysis for chemotherapy resistance.
OR | 95% CI | P-value | |
---|---|---|---|
miRNA | |||
miR-1234-3p | 0.26 | 0.11–0.64 | 0.003 |
Histologic type | |||
Serous adenocarcinoma | - | - | - |
Mucinous adenocarcinoma | 0.27 | 0.03–2.44 | 0.244 |
Endometrioid adenocarcinoma | 1.34 | 0.22–8.16 | 0.754 |
Clear Cell adenocarcinoma | 5.22 | 0.72–37.83 | 0.102 |
FIGO stage | |||
I | |||
II | 55.70 | 0.00–1.8873 | 0.962 |
III | 105.63 | 0.00–3.5473 | 0.956 |
IV | 184.28 | 0.00–6.1873 | 0.951 |
Age per 10 years | 1.08 | 0.73–1.60 | 0.707 |
Performance score1 low vs. high | 0.88 | 0.49–1.55 | 0.648 |
BMI group | |||
18.5–25 | - | - | - |
<18.5 | 968.93 | 0.00–6.47155 | 0.968 |
>25–30 | 0.09 | 0.00–7.9349 | 0.968 |
>30 | 0.18 | 0.00–1.6050 | 0.977 |
Residual tumor | |||
Yes | - | - | - |
No | 0.45 | 0.25–0.80 | 0.0064 |
OR = odds ratio, CI = confidence interval, FIGO = International Federation of Gynecology and
Obstetrics.
1WHO/Eastern Cooperative Oncology Group performance score.